Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Hengstenberg C, Chandrasekhar J, Sartori S, Lefevre T, Mikhail G, Meneveau N, Tron C, Jeger R, Kupatt C, Vogel B, Farhan S, Sorrentino S, Sharma M, Snyder C, Husser O, Boekstegers P, Hambrecht R, Widder J, Hildick-Smith D, De Carlo M, Wijngaard P, Deliargyris E, Bernstein D, Baber U, Mehran R, Anthopoulos P, Dangas G; BRAVO-3 Investigators.
Hengstenberg C, et al. Among authors: mehran r.
Catheter Cardiovasc Interv. 2017 Nov 15;90(6):1027-1037. doi: 10.1002/ccd.27155. Epub 2017 Jun 20.
Catheter Cardiovasc Interv. 2017.
PMID: 28493641
Clinical Trial.